Medicare Advantage beneficiaries had higher risk-adjusted 30-day readmission rates than traditional Medicare beneficiaries for AMI (17.2% vs 16.9%), CHF (21.7% vs 21.4%), and pneumonia (16.5% vs 16.0%).
Cohort (n=4,320,630)
Yes
Does Medicare Advantage enrollment reduce 30-day readmissions compared to traditional Medicare in older adults hospitalized for AMI, CHF, or pneumonia?
Risk-adjusted 30-day readmission rates for AMI, CHF, and pneumonia are slightly higher among Medicare Advantage beneficiaries compared to those in traditional Medicare.
Effect estimate: Difference 0.3 percentage points (95% CI 0.1 to 0.5)
Absolute Event Rate: 17.2% vs 16.9%
Background: Medicare's Hospital Readmissions Reduction Program reports risk-standardized readmission rates for traditional Medicare but not Medicare Advantage beneficiaries. Objective: To compare readmission rates between Medicare Advantage and traditional Medicare. Design: Retrospective cohort study linking the Medicare Provider Analysis and Review (MedPAR) file with the Healthcare Effectiveness Data and Information Set (HEDIS). Setting: 4748 U.S. acute care hospitals. Patients: Patients aged 65 years or older hospitalized for acute myocardial infarction (AMI) (n = 841 613), congestive heart failure (CHF) (n = 1 458 652), or pneumonia (n = 2 020 365) between 2011 and 2014. Measurements: 30-day readmissions. Results: Among admissions for AMI, CHF, and pneumonia identified in MedPAR, 29.2%, 38.0%, and 37.2%, respectively, did not have a corresponding record in HEDIS. Of these, 18.9% for AMI, 23.7% for CHF, and 18.3% for pneumonia resulted in a readmission that was identified in MedPAR. However, among index admissions appearing in HEDIS, 14.4% for AMI, 18.4% for CHF, and 13.9% for pneumonia resulted in a readmission. Patients in Medicare Advantage had lower unadjusted readmission rates than those in traditional Medicare for all 3 conditions (16.6% vs. 17.1% for AMI, 21.4% vs. 21.7% for CHF, and 16.3% vs. 16.4% for pneumonia). However, after standardization, patients in Medicare Advantage had higher readmission rates than patients in traditional Medicare for AMI (17.2% vs. 16.9%; difference, 0.3 percentage point 95% CI, 0.1 to 0.5 percentage point), CHF (21.7% vs. 21.4%; difference, 0.3 percentage point CI, 0.2 to 0.5 percentage point), and pneumonia (16.5% vs. 16.0%; difference, 0.5 percentage point 95% CI, 0.4 to 0.6 percentage point). Rate differences increased between 2011 and 2014. Limitation: Potential unobserved differences between populations. Conclusion: The HEDIS data underreported hospital admissions for 3 common medical conditions, and readmission rates were higher among patients with underreported admissions. Medicare Advantage beneficiaries had higher risk-adjusted 30-day readmission rates than traditional Medicare beneficiaries. Primary Funding Source: National Institute on Aging.
Panagiotou et al. (Tue,) conducted a cohort in Acute myocardial infarction, congestive heart failure, or pneumonia (n=4,320,630). Medicare Advantage vs. Traditional Medicare was evaluated on Risk-standardized 30-day readmission for acute myocardial infarction (Difference 0.3 percentage points, 95% CI 0.1 to 0.5). Medicare Advantage beneficiaries had higher risk-adjusted 30-day readmission rates than traditional Medicare beneficiaries for AMI (17.2% vs 16.9%), CHF (21.7% vs 21.4%), and pneumonia (16.5% vs 16.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: